TNBC, an aggressive form of breast cancer with a poor prognosis, lacks estrogen and progesterone receptors, as well as the HER2 protein, rendering both hormone therapy and HER2-targeting drugs ineffective. This evidence concerns the gene PGR and breast cancer.